CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 38 enrolled
Drug / intervention
Aripiprazole +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00345033
NCT00345033Phase 4Completed
CompareCT.gov

Aripiprazole for Clozapine Associated Medical Morbidity

Massachusetts General Hospital·interventional·Posted Jun 27, 2006·Updated Jun 23, 2014

In Brief

A Phase 4 clinical trial evaluating Aripiprazole and Placebo for Schizophrenia and Insulin Resistance. Completed, enrolled 38 participants across 1 site.

Detailed Summary

This study will evaluate the effects of combination treatment with aripiprazole and clozapine on insulin resistance, blood fat levels, and weight gain in people diagnosed with schizophrenia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia, Insulin Resistance
CountriesUnited States
CollaboratorsNational Institute of Mental Health (NIMH)

Timeline

Phase 4CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 27, 2006
Enrollment StartMar 1, 2005
Primary CompletionOct 1, 2009
Study CompletionOct 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 20.0 years ago

Interventions

Aripiprazoledrug

15-mg dose once a day for 8 weeks

Placebodrug

1 tablet placebo dose once a day for 8 weeks